ECSP19030134A - Compuesto de piridina - Google Patents

Compuesto de piridina

Info

Publication number
ECSP19030134A
ECSP19030134A ECSENADI201930134A ECDI201930134A ECSP19030134A EC SP19030134 A ECSP19030134 A EC SP19030134A EC SENADI201930134 A ECSENADI201930134 A EC SENADI201930134A EC DI201930134 A ECDI201930134 A EC DI201930134A EC SP19030134 A ECSP19030134 A EC SP19030134A
Authority
EC
Ecuador
Prior art keywords
pyridine compound
pharmaceutically acceptable
acceptable salt
compound
formula
Prior art date
Application number
ECSENADI201930134A
Other languages
English (en)
Inventor
Yasuyuki Kaneta
Yoshihiro Shibata
Hiroaki Inagaki
Hidenori Namiki
Kiyoshi Nakayama
Hideaki Kageji
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of ECSP19030134A publication Critical patent/ECSP19030134A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención tiene relación con un compuesto que tiene acción inhibidora de quinasa RET o una sal farmacéuticamente aceptable del mismo, útil en el tratamiento de enfermedades como cáncer. En particular un compuesto representado por la siguiente fórmula general (I) como se define en este documento: [Fórmula I] (ver figura) o una sal farmacéuticamente aceptable del mismo.
ECSENADI201930134A 2016-09-29 2019-04-29 Compuesto de piridina ECSP19030134A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016191725A JP2018052878A (ja) 2016-09-29 2016-09-29 ピリジン化合物
PCT/GB2017/052913 WO2018060714A1 (en) 2016-09-29 2017-09-28 Pyridine compound

Publications (1)

Publication Number Publication Date
ECSP19030134A true ECSP19030134A (es) 2019-08-30

Family

ID=60020249

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201930134A ECSP19030134A (es) 2016-09-29 2019-04-29 Compuesto de piridina

Country Status (33)

Country Link
US (2) US10851092B2 (es)
EP (2) EP3519398B1 (es)
JP (2) JP2018052878A (es)
KR (1) KR102520543B1 (es)
CN (2) CN110036007B (es)
AU (2) AU2017335242C1 (es)
BR (1) BR112019006047A2 (es)
CA (1) CA3035860A1 (es)
CL (1) CL2019000844A1 (es)
CO (1) CO2019004034A2 (es)
CY (1) CY1123988T1 (es)
DK (1) DK3519398T3 (es)
EA (1) EA037103B1 (es)
EC (1) ECSP19030134A (es)
ES (1) ES2868748T3 (es)
HR (1) HRP20210447T1 (es)
HU (1) HUE054824T2 (es)
IL (1) IL265630B (es)
LT (1) LT3519398T (es)
MA (2) MA46337B1 (es)
MD (1) MD3519398T2 (es)
MX (1) MX2019003747A (es)
PE (1) PE20190805A1 (es)
PH (1) PH12019500480A1 (es)
PL (1) PL3519398T3 (es)
PT (1) PT3519398T (es)
RS (1) RS61640B1 (es)
SG (1) SG11201901937WA (es)
SI (1) SI3519398T1 (es)
SM (1) SMT202100315T1 (es)
UA (1) UA123964C2 (es)
WO (1) WO2018060714A1 (es)
ZA (1) ZA201902232B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3371171B1 (en) 2015-11-02 2023-10-25 Blueprint Medicines Corporation Inhibitors of ret
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
BR112020020273A2 (pt) 2018-04-03 2021-04-06 Blueprint Medicines Corporation Inibidor de ret para uso no tratamento de câncer tendo uma alteração de ret
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
US20230019999A1 (en) * 2019-11-18 2023-01-19 Chugai Seiyaku Kabushiki Kaisha Combination drug
CN113121524B (zh) 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021164741A1 (zh) * 2020-02-20 2021-08-26 南京明德新药研发有限公司 苯基双酰胺类化合物
CN117903123A (zh) * 2020-02-20 2024-04-19 广州白云山医药集团股份有限公司白云山制药总厂 喹啉类化合物
EP4157829A1 (en) 2020-05-29 2023-04-05 Blueprint Medicines Corporation Solid forms of pralsetinib
WO2022238706A1 (en) 2021-05-14 2022-11-17 Bp Asset Viii, Inc. Ret inhibitor for the treatment of ret altered medullary thyroid cancer or ret altered non-small cell lung cancer
CA3234317A1 (en) 2021-10-22 2023-12-14 Wa Xian Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues
CN115090331B (zh) * 2022-07-21 2023-05-16 扬州大学 超分子手性催化剂、其制备方法及其催化d-a反应的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
EP1670787B1 (en) 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
JP2009528335A (ja) 2006-03-02 2009-08-06 アストラゼネカ アクチボラグ キナゾリン誘導体
EP1994024A2 (en) 2006-03-02 2008-11-26 AstraZeneca AB Quinoline derivatives
WO2007113565A1 (en) 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
WO2007113548A1 (en) 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives
FR2933700B1 (fr) * 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
PL2404908T3 (pl) * 2009-02-27 2014-12-31 Teijin Ltd Sposób wytwarzania podstawionej fenylem pochodnej heterocyklicznej przez sprzężenie z użyciem katalizatora metalu przejściowego
BR112012003661A2 (pt) 2009-08-19 2017-04-25 Ambit Biosciences Corp "compostos de biarila e métodos de uso dos mesmos."
CN102573832B (zh) * 2009-08-25 2015-07-22 阿布拉科斯生物科学有限公司 利用紫杉烷和刺猬抑制剂的纳米颗粒组合物的联合治疗
CA2798209A1 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
EP2651930B1 (en) 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
WO2014012050A2 (en) 2012-07-13 2014-01-16 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
AU2014229233B2 (en) 2013-03-15 2016-08-11 Glaxosmithkline Intellectual Property Development Limited Pyridine derivatives as rearranged during transfection (RET) kinase inhibitors
EP3039021A1 (en) * 2013-08-30 2016-07-06 Ambit Biosciences Corporation Biaryl acetamide compounds and methods of use thereof
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
US9783522B2 (en) * 2014-04-24 2017-10-10 Mitsubishi Tanabe Pharma Corporation 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof
RS58813B1 (sr) * 2014-09-10 2019-07-31 Glaxosmithkline Ip Dev Ltd Piridonski derivati korišćeni kao inhibitori kinaze reorganizovane tokom transfekcije (ret)
MX381233B (es) * 2014-09-10 2025-03-12 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret).
CA2964113A1 (en) 2014-10-14 2016-04-21 La Jolla Institute Of Allergy & Immunology Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
CN104844589B (zh) * 2014-12-26 2018-04-20 中国科学院合肥物质科学研究院 一种pi3k激酶抑制剂
WO2016127074A1 (en) * 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
PT3322706T (pt) 2015-07-16 2021-03-08 Array Biopharma Inc Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物

Also Published As

Publication number Publication date
US10851092B2 (en) 2020-12-01
MX2019003747A (es) 2019-09-19
JP2019534871A (ja) 2019-12-05
ES2868748T3 (es) 2021-10-21
PT3519398T (pt) 2021-03-24
CA3035860A1 (en) 2018-04-05
IL265630B (en) 2021-10-31
PH12019500480A1 (en) 2019-08-05
RS61640B1 (sr) 2021-04-29
JP7098609B2 (ja) 2022-07-11
PL3519398T3 (pl) 2021-06-28
EP3519398A1 (en) 2019-08-07
SI3519398T1 (sl) 2021-07-30
CN113788824A (zh) 2021-12-14
EA201990833A1 (ru) 2019-10-31
CN110036007A (zh) 2019-07-19
CO2019004034A2 (es) 2019-07-10
UA123964C2 (uk) 2021-06-30
AU2021261899A1 (en) 2021-12-02
JP2018052878A (ja) 2018-04-05
HRP20210447T1 (hr) 2021-07-23
HUE054824T2 (hu) 2021-10-28
LT3519398T (lt) 2021-05-10
PE20190805A1 (es) 2019-06-10
EA037103B1 (ru) 2021-02-05
SG11201901937WA (en) 2019-04-29
CL2019000844A1 (es) 2019-06-07
IL265630A (en) 2019-05-30
ZA201902232B (en) 2022-12-21
MA46337A (fr) 2019-08-07
US20200039974A1 (en) 2020-02-06
AU2017335242A1 (en) 2019-05-02
BR112019006047A2 (pt) 2019-06-25
AU2017335242C1 (en) 2021-12-09
MD3519398T2 (ro) 2021-05-31
EP3519398B1 (en) 2021-02-24
SMT202100315T1 (it) 2021-07-12
KR20190086442A (ko) 2019-07-22
AU2017335242B2 (en) 2021-08-19
EP3828178A1 (en) 2021-06-02
DK3519398T3 (da) 2021-03-29
US20210163464A1 (en) 2021-06-03
MA54910A (fr) 2022-04-13
MA46337B1 (fr) 2021-04-30
KR102520543B1 (ko) 2023-04-10
CY1123988T1 (el) 2022-05-27
WO2018060714A1 (en) 2018-04-05
CN110036007B (zh) 2021-10-15

Similar Documents

Publication Publication Date Title
ECSP19030134A (es) Compuesto de piridina
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
ECSP18093777A (es) Derivados de pirazolopirimidina como inhibidor de quinasa
DOP2020000112A (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
CL2020001754A1 (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa.
ECSP20035588A (es) Derivado de amino-metil piperidina como inhibidor de quinasa
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
PE20151654A1 (es) Inhibidores de cdc7
MX2015006039A (es) Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer.
MX2017015277A (es) Derivado de pirido[3,4-d]pirimidina y sal farmaceuticamente aceptable de este.
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
MX2017000208A (es) Derivados de quinolizinona como inhibidores de pi3k.
MX2019002369A (es) Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial.
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
MX2017006110A (es) Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
UY35317A (es) Compuesto de ciclopropanoamina